N@N

Market Maker Surveillance Report. PRX, ALNY, IBIO, ANTH, AXST, TKMR, Winning Stocks With Lowest Price Friction For Monday, Jul

July 16, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3938 companies with "abnormal" market making, 2211 companies with positive Friction Factors and 3045 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Par Pharmaceutical Companies Inc (NYSE:PRX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), Ibio Inc (AMEX:IBIO), Anthera Pharmaceuticals Inc (NASDAQ:ANTH), AXESSTEL INC (OTC:AXST), TEKMIRA PHARMACEUTICALS CORP (NASDAQ:TKMR). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  PRX     $13.410   36.66%    3,936,283    33.32%    3,853,196    32.62%    83,087       62      
  ALNY    $6.620    52.88%    4,824,646    50.26%    4,631,845    48.25%    192,801      291     
  IBIO    $0.250    31.25%    224,409      40.27%    153,010      27.45%    71,399       2,856   
  ANTH    $0.610    85.84%    12,854,631   55.62%    10,252,943   44.36%    2,601,688    42,651  
  AXST    $0.200    18.18%    60,504       51.07%    35,226       29.73%    25,278       1,264   
  TKMR    $0.530    23.67%    180,550      56.18%    138,812      43.19%    41,738       788     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows PRX with a dollar gain Monday of $13.41000 and a Friction Factor of 62 shares. That means that it only took 62 more shares of buying than selling to move PRX higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Par Pharmaceutical Companies Inc (NYSE:PRX) - Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. engages in the development, manufacture, and distribution of generic and branded drugs in the United States. Its principal generic products include Metoprolol succinate ER, Sumatriptan succinate injection, Meclizine Hydrochloride, Clonidine TDS, Dronabinol, Cabergoline, Propranolol HCl ER, Cholestyramine Powder, Methimazole, Megestrol oral suspension, Tramadol HCl and acetaminophen tablets, Fluticasone, Ibuprofen Rx, and various amoxicillin products. The company offers its drugs in solid oral dosage forms, such as tablets, caplets, and two-piece hard-shell capsules; oral suspension products; nasal spray products; products delivered by injection; and products in the semi-solid form of a cream and a transdermal patch. Its brand products include Megace ES drugs for the treatment of anorexia, cachexia, or any unexplained significant weight loss in patients with a diagnosis of AIDS; Nascobal Nasal Spray, a prescription vitamin B12 treatment indicated for maintenance of remission in certain pernicious anemia patients, as well as a supplement for various B12 deficiencies; and Androgel, a testosterone gel indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Par Pharmaceutical plans to launch Zuplenz, an oral soluble thin film formulation for the prevention of chemotherapy induced nausea and vomiting, and post-operative nausea and vomiting; and Oravig, a miconozole antifungal therapy for the treatment of oropharyngeal candidiasis. It markets its products to wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, managed health care organizations, mail order accounts, drug distributors, nursing homes, hospitals, clinics, government agencies, and pharmacy benefit management companies. The company was founded in 1978 and is based in Woodcliff Lake, New Jersey.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) - Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). Its lead RNAi therapeutic program includes ALN-RSV01, which is in Phase II clinical trial for the treatment of human respiratory syncytial virus (RSV) infection. The companys product pipeline also comprises ALN-VSP, a Phase I clinical trial product to treat liver cancers. Its products under development stage include ALN-RSV02 for the treatment of RSV infection; ALN TTR01 and ALN TTR02 to treat TTR-Mediated Amyloidosis; ALN-PCS for the treatment of PCSK9/Hypercholesterolemia; and ALN-HTT to treat Huntingtons disease. It has license and collaboration agreements with Roche to develop and commercialize therapeutic products that function through RNAi; Takeda for the development and commercialization of RNAi therapeutics; and with Medtronic Inc. and CHDI Foundation, Inc. to advance ALN-HTT, a novel drug-device combination for the treatment of Huntington's disease. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Ibio Inc (AMEX:IBIO) - iBio, Inc., a biopharmaceutical company, focuses on the development of vaccines and therapeutic proteins based upon its proprietary plant-based iBioLaunch Platform Technology. The company principally focuses on advancing a H1N1 influenza vaccine candidate to clinical trials and to establish business arrangements for use of the technology by licensees for the development and production of other products for the prevention and treatment of various infectious diseases, including influenza, anthrax, and human papilloma virus. iBio holds a research and development agreement with the Fraunhofer USA Center for Molecular Biotechnology and has exclusive rights to the proprietary platform developed under the agreement for human health applications for developing vaccines and therapeutic products for a broad range of medical indications and for veterinary applications of plant-based influenza vaccines. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio is headquartered in Newark, Delaware.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) - Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

AXESSTEL INC (OTC:AXST) - Axesstel, Inc. provides fixed wireless voice and broadband access solutions for the telecommunications market worldwide. The company offers fixed wireless phones, such as fixed wireless desktop phones for voice and data usage in homes, businesses, and retail locations; fixed wireless public call office phones that enable telecommunications service providers to offer telephone service for public locations that are not serviced by landline networks; and fixed wireless voice/data terminals, which provide Internet access, voice service, and facsimile services. It also provides wireless broadband modem products, including USB modem, USB dongle, and expresscard/34 that enable mobile professionals to access email, the Internet, data intensive files, and multi-media streaming from home, office, or while traveling by plugging the device into their laptop or desktop; and 3G gateway products, which combine wireless wide area networking, a Wi-Fi wireless local area network router and a four-port Ethernet switch to provide wireless broadband data access via a plug-and-play solution. In addition, the company offers VoIP gateway devices; and AxessGuard M2M security devices that provide security system for residences and businesses by pairing a motion sensing security device with one of the fixed wireless phones or terminals to generate an alert via short message service or phone call in the event of a security breach. Axesstel sells its products to telecommunications service providers through direct sales team and distributors. The company was founded in 2000 and is headquartered in San Diego, California.

TEKMIRA PHARMACEUTICALS CORP (NASDAQ:TKMR) - Tekmira Pharmaceuticals Corp., a biopharmaceutical company, focuses on advancing ribonucleic acid (RNA) interference therapeutics and providing its lipid nanoparticle delivery technology to pharmaceutical partners. Its lead internal product candidates include apolipoprotein B (ApoB) stable nucleic acid lipid particles (SNALP) for the treatment of high cholesterol and polo-like kinase 1 (PLK1) SNALP for the treatment of cancer. The company has various collaborative and licensing agreements with Alnylam Pharmaceuticals, Inc.; Roche; Bristol-Myers Squibb Company; Hana Biosciences, Inc.; Merck & Co., Inc.; and Aradigm Corporation. Tekmira Pharmaceuticals Corp. was formerly a subsidiary of Primary Corp. Tekmira Pharmaceuticals Corp. is headquartered in Burnaby, Canada.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net